2021
SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer
Chung H, Lee K, Kim W, Gainor J, Lakhani N, Chow L, Messersmith W, Fanning P, Squifflet P, Jin F, Forgie A, Wan H, Pons J, Randolph S, LoRusso P. SO-31 ASPEN-01: A phase 1 study of ALX148, a CD47 blocker, in combination with trastuzumab, ramucirumab and paclitaxel in patients with second-line HER2-positive advanced gastric or gastroesophageal junction cancer. Annals Of Oncology 2021, 32: s215-s216. DOI: 10.1016/j.annonc.2021.05.055.Peer-Reviewed Original Research
2019
SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF)
Chau I, Bendell J, Soriano A, Arkenau H, Cultrera J, Santana-Davila R, Calvo E, Le Tourneau C, Zender L, Mi G, Schelman W, Ferry D, Herbst R, Fuchs C. SO-002 Safety and antitumor activity from the phase Ib study of ramucirumab plus pembrolizumab in treatment-naïve advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma (JVDF). Annals Of Oncology 2019, 30: iv122. DOI: 10.1093/annonc/mdz157.001.Peer-Reviewed Original Research
2016
A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results.
Herbst R, Bendell J, Isambert N, Calvo E, Santana-Davila R, Cassier P, Perez-Gracia J, Yang J, Rege J, Ferry D, Mi G, Chau I. A phase 1 study of ramucirumab (R) plus pembrolizumab (P) in patients (pts) with advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma, non-small cell lung cancer (NSCLC), or urothelial carcinoma (UC): Phase 1a results. Journal Of Clinical Oncology 2016, 34: 3056-3056. DOI: 10.1200/jco.2016.34.15_suppl.3056.Peer-Reviewed Original Research
2012
Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers
Ishida K, Nishizuka SS, Chiba T, Ikeda M, Kume K, Endo F, Katagiri H, Matsuo T, Noda H, Iwaya T, Yamada N, Fujiwara H, Takahashi M, Itabashi T, Uesugi N, Maesawa C, Tamura G, Sugai T, Otsuka K, Koeda K, Wakabayashi G. Molecular Marker Identification for Relapse Prediction in 5-FU-Based Adjuvant Chemotherapy in Gastric and Colorectal Cancers. PLOS ONE 2012, 7: e43236. PMID: 22905237, PMCID: PMC3419205, DOI: 10.1371/journal.pone.0043236.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntimetabolites, AntineoplasticBiomarkers, TumorCell Line, TumorChemotherapy, AdjuvantCluster AnalysisColorectal NeoplasmsFluorouracilGene Expression Regulation, NeoplasticHumansImmunohistochemistryMAP Kinase Kinase 4Middle AgedPrognosisRecurrenceRNA, Small InterferingStomach NeoplasmsConceptsAdjuvant chemotherapyNF-κBCancer patientsTissue microarrayProtein expressionColorectal cancer patientsOverall survival rateGastrointestinal tract cancerGastric cancer patientsGastric cancer cell linesCell linesCancer cell linesJNK protein expressionR0 resectionTract cancerColorectal cancerImmunohistochemical examinationClinical significanceSurvival rateRelapse predictionBaseline expressionChemotherapyChemosensitivity markerPatientsGastricCorrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers
Laine L, Kivitz A, Bello A, Grahn A, Schiff M, Taha A. Corrigendum: Double-Blind Randomized Trials of Single-Tablet Ibuprofen/High-Dose Famotidine vs. Ibuprofen Alone for Reduction of Gastric and Duodenal Ulcers. The American Journal Of Gastroenterology 2012, 107: 1272. DOI: 10.1038/ajg.2012.244.Peer-Reviewed Original ResearchSurgical Treatment of Peritoneal Carcinomatosis from Gastric Cancer
Turaga K, Gamblin T, Pappas S. Surgical Treatment of Peritoneal Carcinomatosis from Gastric Cancer. International Journal Of Surgical Oncology 2012, 2012: 405652. PMID: 22778938, PMCID: PMC3388312, DOI: 10.1155/2012/405652.Peer-Reviewed Original ResearchPeritoneal carcinomatosisApplication of cytoreductive surgeryGastric cancerTreatment of peritoneal carcinomatosisLimited treatment optionsHyperthermic chemoperfusionCytoreductive surgerySystemic chemotherapyIntraperitoneal lavageSurgical treatmentNovel therapiesTreatment optionsDisease processCarcinomatosisFatal diseaseDiseaseCancerChemoperfusionChemotherapyLavageSurgeryIntraperitonealTherapyGastricA novel antireflux procedure: gastroplasty with restricted antrum to control emesis (GRACE)
Neff LP, Becher RD, Blackham AU, Banks NA, Mitchell EL, Petty JK. A novel antireflux procedure: gastroplasty with restricted antrum to control emesis (GRACE). Journal Of Pediatric Surgery 2012, 47: 99-106. PMID: 22244400, DOI: 10.1016/j.jpedsurg.2011.10.024.Peer-Reviewed Original ResearchConceptsNissen fundoplicationAntireflux procedureNeurologic impairmentGastric emptyingGastroesophageal reflux diseaseGastrostomy tube placementReflux diseaseGastric functionTube placementBaseline gastricFundoplicationCanine modelRefluxEmesisAntrumEmptyingCanine subjectsFunctional disadvantagesImpairmentFailure rateChildrenSubjectsGastroplastyVomitingGastric
2008
Simultaneous Gastric and Small Intestinal Trichobezoars
Malhotra A, Jones L, Drugas G. Simultaneous Gastric and Small Intestinal Trichobezoars. Pediatric Emergency Care 2008, 24: 774-776. PMID: 19018222, DOI: 10.1097/pec.0b013e31818c2891.Peer-Reviewed Original Research
2005
Role of potassium in acid secretion
Geibel JP. Role of potassium in acid secretion. World Journal Of Gastroenterology 2005, 11: 5259-5265. PMID: 16149129, PMCID: PMC4622792, DOI: 10.3748/wjg.v11.i34.5259.Peer-Reviewed Original Research
1994
Pathophysiology of gastroesophageal reflux disease
Ravich W. Pathophysiology of gastroesophageal reflux disease. Current Opinion In Otolaryngology & Head & Neck Surgery 1994, 2: 74-79. DOI: 10.1097/00020840-199402000-00016.Peer-Reviewed Original ResearchGastroesophageal reflux diseaseReflux diseaseExtraesophageal manifestationsExtraesophageal presentationsPoor gastricGastric hypersecretionEsophageal manifestationsAcid suppressionAntireflux barrierEsophageal clearanceDiseasePharynxManifestationsCurrent understandingHypersecretionRegurgitationAirwayPathophysiologyEsophagusGastricCentral roleClearance
1988
C-14 UREA BREATH TEST IN CAMPYLOBACTER PYLORIDIS GASTRIC DISORDERS
Drew H, LaFrance N, Mertz H, Hernandez J, Ravich W, Milligan F, Bartlett J, Yardley J, Hendrix T. C-14 UREA BREATH TEST IN CAMPYLOBACTER PYLORIDIS GASTRIC DISORDERS. Clinical Nuclear Medicine 1988, 13: 394. DOI: 10.1097/00003072-198805000-00046.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply